Detalles de la búsqueda
1.
Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance).
Breast Cancer Res Treat
; 160(2): 297-304, 2016 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-27704226
2.
Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance).
Ann Surg
; 262(3): 434-9; discussion 438-9, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26222764
3.
Adjuvant chemotherapy in older women with early-stage breast cancer.
N Engl J Med
; 360(20): 2055-65, 2009 May 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-19439741
4.
Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial.
J Clin Oncol
; 37(26): 2338-2348, 2019 09 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31339827
5.
The impact of actual body weight-based chemotherapy dosing and body size on adverse events and outcome in older patients with breast cancer: Results from Cancer and Leukemia Group B (CALGB) trial 49907 (Alliance A151436).
J Geriatr Oncol
; 9(3): 228-234, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29233548
6.
Use of the National Institutes of Health Consensus Guidelines Improves the Diagnostic Sensitivity of Gastrointestinal Graft-Versus-Host Disease.
Arch Pathol Lab Med
; 142(9): 1098-1105, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29697275
7.
Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative).
J Am Coll Surg
; 224(4): 688-694, 2017 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-28089784
8.
Effect of Pretreatment Renal Function on Treatment and Clinical Outcomes in the Adjuvant Treatment of Older Women With Breast Cancer: Alliance A171201, an Ancillary Study of CALGB/CTSU 49907.
J Clin Oncol
; 34(7): 699-705, 2016 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26755510
9.
Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance).
J Clin Oncol
; 34(22): 2602-9, 2016 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27138575
10.
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.
J Clin Oncol
; 34(6): 542-9, 2016 Feb 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-26527775
11.
Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.
J Clin Oncol
; 21(9): 1825-35, 2003 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-12721260
12.
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.
J Clin Oncol
; 21(6): 976-83, 2003 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-12637460
13.
Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance).
J Natl Cancer Inst
; 107(9)2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26113580
14.
Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).
J Clin Oncol
; 33(1): 13-21, 2015 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25092775
15.
Methodological considerations in the design and implementation of clinical trials.
Semin Oncol Nurs
; 30(1): 74-9, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24559783
16.
Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance).
J Clin Oncol
; 32(35): 3959-66, 2014 Dec 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-25348000
17.
Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance).
J Clin Oncol
; 32(22): 2311-7, 2014 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24934787
18.
Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343.
J Clin Oncol
; 31(19): 2382-7, 2013 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23690420
19.
Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101.
J Clin Oncol
; 30(33): 4071-6, 2012 Nov 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-22826271
20.
Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401.
J Clin Oncol
; 29(10): 1290-6, 2011 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21357782